JP2021513865A - 修飾PlySs2溶解素及びその使用 - Google Patents

修飾PlySs2溶解素及びその使用 Download PDF

Info

Publication number
JP2021513865A
JP2021513865A JP2020544642A JP2020544642A JP2021513865A JP 2021513865 A JP2021513865 A JP 2021513865A JP 2020544642 A JP2020544642 A JP 2020544642A JP 2020544642 A JP2020544642 A JP 2020544642A JP 2021513865 A JP2021513865 A JP 2021513865A
Authority
JP
Japan
Prior art keywords
modified
polypeptide
seq
amino acid
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513865A5 (cg-RX-API-DMAC7.html
Inventor
レイモンド シューフ
レイモンド シューフ
キアラ インディアニ
キアラ インディアニ
マイケル ウィッテキンド
マイケル ウィッテキンド
Original Assignee
コントラフェクト コーポレイション
コントラフェクト コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コントラフェクト コーポレイション, コントラフェクト コーポレイション filed Critical コントラフェクト コーポレイション
Publication of JP2021513865A publication Critical patent/JP2021513865A/ja
Publication of JP2021513865A5 publication Critical patent/JP2021513865A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020544642A 2018-02-26 2019-02-26 修飾PlySs2溶解素及びその使用 Pending JP2021513865A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862635515P 2018-02-26 2018-02-26
US62/635,515 2018-02-26
PCT/US2019/019638 WO2019165454A1 (en) 2018-02-26 2019-02-26 Modified plyss2 lysins and uses thereof

Publications (2)

Publication Number Publication Date
JP2021513865A true JP2021513865A (ja) 2021-06-03
JP2021513865A5 JP2021513865A5 (cg-RX-API-DMAC7.html) 2022-02-09

Family

ID=67687985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544642A Pending JP2021513865A (ja) 2018-02-26 2019-02-26 修飾PlySs2溶解素及びその使用

Country Status (12)

Country Link
US (1) US20210032294A1 (cg-RX-API-DMAC7.html)
EP (1) EP3758738A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021513865A (cg-RX-API-DMAC7.html)
KR (1) KR20200124724A (cg-RX-API-DMAC7.html)
CN (1) CN112118861A (cg-RX-API-DMAC7.html)
AU (1) AU2019224160A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017219A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092109A1 (cg-RX-API-DMAC7.html)
IL (1) IL276807A (cg-RX-API-DMAC7.html)
MX (1) MX2020008860A (cg-RX-API-DMAC7.html)
RU (1) RU2020128276A (cg-RX-API-DMAC7.html)
WO (1) WO2019165454A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020271116A1 (en) * 2019-04-11 2021-11-11 Contrafect Corporation Method of treating and preventing bone and joint infections
US20230277632A1 (en) * 2020-05-19 2023-09-07 Contrafect Corporation MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA
WO2023049747A1 (en) * 2021-09-22 2023-03-30 Elanco Us Inc. Streptococcus suis lytic enzyme compositions and methods of use thereof
WO2023081691A1 (en) * 2021-11-04 2023-05-11 Contrafect Corporation Method of treating and preventing bone and joint infections
CN115851689A (zh) * 2022-08-09 2023-03-28 中南民族大学 一种嵌合裂解酶PlySs2E-V12C及其应用、重组质粒和重组菌株

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518849A (ja) * 2011-04-21 2014-08-07 ザ ロックフェラー ユニバーシティ グラム陽性細菌を検出および処置するためのStreptococcusバクテリオファージリシン

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3085777T3 (da) * 2011-05-04 2020-02-03 Micreos Human Health Bv Polypeptid
AU2013259512B2 (en) * 2012-05-09 2018-01-25 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria
RU2646102C2 (ru) * 2012-05-09 2018-03-01 Контрафект Корпорейшн Предотвращение, разрушение и обработка биопленки лизином бактериофага
CN104073478A (zh) * 2014-06-13 2014-10-01 上海交通大学 杀灭革兰氏阳性菌的酶抗生素及其制备、用途
CN104211781A (zh) * 2014-09-04 2014-12-17 北京纳百景弈生物科技有限公司 金黄色葡萄球菌裂解蛋白的制备方法及其应用
CN109152822B (zh) * 2016-05-12 2023-12-05 抗非特公司 用于评估和确定抗菌多肽的最小抑制浓度的肉汤微量稀释法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518849A (ja) * 2011-04-21 2014-08-07 ザ ロックフェラー ユニバーシティ グラム陽性細菌を検出および処置するためのStreptococcusバクテリオファージリシン

Also Published As

Publication number Publication date
MX2020008860A (es) 2020-12-10
AU2019224160A1 (en) 2020-09-10
IL276807A (en) 2020-10-29
BR112020017219A2 (pt) 2020-12-22
EP3758738A4 (en) 2021-12-08
KR20200124724A (ko) 2020-11-03
WO2019165454A1 (en) 2019-08-29
EP3758738A1 (en) 2021-01-06
CA3092109A1 (en) 2019-08-29
US20210032294A1 (en) 2021-02-04
CN112118861A (zh) 2020-12-22
RU2020128276A (ru) 2022-03-29

Similar Documents

Publication Publication Date Title
CN108348574B (zh) 具有对抗革兰氏阴性菌的活性的溶素多肽
JP7646237B2 (ja) シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定
US20210032294A1 (en) MODIFIED PlySs2 LYSINS AND USES THEREOF
US20210260070A1 (en) Lysin cf-301 resensitizes methicillin-resistant staphylococcus aureua (mrsa) to penicillin derivatives and first generation cephalosporins
KR20210005027A (ko) 항미생물성 박테리오파지 유도된 폴리펩타이드 및 그람 음성 세균에 대한 이의 용도
KR20230162045A (ko) 그램-음성 박테리아에 대해 활성인 아무린, 리신, 및 리신-항미생물 펩타이드 (amp) 작제물
JP2022526978A (ja) ヒト血清の存在下でシュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体
CN117377680A (zh) 针对革兰氏阴性细菌有活性的amurin溶素和溶素-抗微生物肽(AMP)构建体
US20220193186A1 (en) Method of treating and preventing bone and joint infections
JP2023526386A (ja) グラム陽性細菌に対して使用される修飾PlySs2溶解素及び抗生物質の組合せ
RU2807688C9 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
RU2807688C2 (ru) Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa
WO2022261360A1 (en) Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240213